TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Manipulation Under Anesthesia Versus Arthroscopic Capsular Release in the Treatment of Adhesive Capsulitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients must be diagnosed as having idiopathic adhesive capsulitis in the 'frozen' or 'thawing' phase of disease and have tried and failed at least 3 months of nonoperative therapy.~OR~* patient with adhesive capsulitis who presents already in the 'frozen' or 'thawing' phase who demands a quicker return to function and will not try 3 months of nonoperative therapy first.~* Age 18 or older~Exclusion Criteria:~* pregnancy~* previously operated shoulder (same side)~* other documented source of shoulder pain and stiffness (same side)~* rotator cuff tear (same side)~* glenohumeral osteoarthritis (same side)~* calcific tendonitis (same side)~* impingement (same side)~* osteonecrosis~* neoplasm~* cervical radiculopathy~* patients who are medically unfit to undergo a general anesthetic~* patients who are unable to comply with the post-operative protocol~* non-English Speaking patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Adhesive Capsulitis with MUA (Type: ACTIVE_COMPARATOR): Subjects with idiopathic adhesive capsulitis in the frozen or thawing phase who have failed pain management and failed improvement in range of motion after at least 3 months of supervised, regimented conservative treatment; or who after less than 3 months of conservative treatment demand a quicker return to function. Treatment closed manipulation under anesthesia.
- Adhesive Capsulitis with Arthroscopy (Type: ACTIVE_COMPARATOR): Subjects with idiopathic adhesive capsulitis in the frozen or thawing phase who have failed pain management and failed improvement in range of motion after at least 3 months of supervised, regimented conservative treatment; or who after less than 3 months of conservative treatment demand a quicker return to function. Treatment Arthroscopic Capsular Release

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* All patients 18 years and older who are already scheduled for primary total joint arthroplasty of the hip or knee~Exclusion Criteria for IV TXA administration~* Cardiac stent or ischemic stroke or coronary artery bypass graft (CABG)~* If patient is on anticoagulant, patient must have documented approval from a cardiologist that patient can be removed from anticoagulant for total joint arthroplasty procedure~* Renal impairment defined as serum Cr \> 1.5 or Cr Clearance \< 50 mL/min~* Severe ischemic heart disease~* Color blindness or problems with color vision~Criteria for Use of Topical TXA~* Topical TXA can be used in any patient meeting one of the exclusion criteria for IV TXA administration (Section 5.3b) as there is minimal systemic absorption with topical TXA~Absolute Exclusion Criteria~* History of deep vein thrombosis (DVT) or pulmonary embolism (PE)~* Known congenital thrombophilia~* History of thromboembolic or vascular disease~* Disseminated intravascular coagulation (DIC)~* History of seizures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous Tranexamic Acid (Type: EXPERIMENTAL): * 1g TXA administered intravenous piggyback at start of surgery OR~* 1g TXA administered intravenous piggyback at start and at time of closure of surgery
- Intravenous Placebo (Type: PLACEBO_COMPARATOR): - IV 0.9% sterile saline
- Intravenous Tranexamic Acid followed by Intravenous Placebo (Type: ACTIVE_COMPARATOR): * 1g TXA administered intravenous piggyback at start of surgery OR~* 1g TXA administered intravenous piggyback at start and at time of closure of surgery~* IV 0.9% sterile saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evoked Retinal Response

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* retinitis pigmentosa~* legally blind in at least one eye~Exclusion Criteria:~* unable to lay down on an exam table

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Retinitis Pigmentosa (Type: EXPERIMENTAL): Subject will have retinitis pigmentosa and will be legally blind in one or both eyes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: In-Vivo Activated T-Cell Depletion to Prevent GVHD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Acute myelogenous leukemia, Acute lymphocytic leukemia, Chronic myelogenous leukemia, Chronic lymphocytic leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Mantle cell, Hodgkin's Disease, Multiple Myeloma, Myelofibrosis with disease-specific eligibility requirements as outlined in the protocol~* Donor Requirement: Must have a fully HLA-matched (10 of 10) related or unrelated donor, eighteen years of age or older, who is capable of undergoing GCSF mobilization and apheresis.~Exclusion Criteria:~* Active CNS disease (the presence of leukemic blasts in the CSF)~* Pregnancy or breast-feeding~* SGOT \>3x upper limit of normal~* Creatinine \>2 or creatinine clearance \<50cc/hr.~* Fractional shortening by echocardiogram not within normal limits per institution~* Pulmonary function: DLCO less that 50% of normal predicted, corrected for anemia~* Prior allogeneic transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. diagnosis of HbSS or HbSBeta0Thal~2. age 10-17 years~3. Weight 30kg or greater~4. Hb 7mg/dL or greater~5. informed consent~Exclusion Criteria:~1. History of vaso-occlusive crisis during the past 6 weeks, or history of transfusion during the past 3 months.~2. pregnancy~3. history of heart failure, myocardial infarction, asthma, bradyarrythmias, hypotension, thyroid disease, diabetes, renal insufficiency~4. concurrent medications: any antihypertensive medication, diuretics, thyroid replacement medications, any arrythmia medication, insulin, hypoglycaemic medication~5. history of allergy to sulfonamides~6. elevated BUN or creatinine

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- cohort 1 10mg propranolol (Type: ACTIVE_COMPARATOR): first study arm will consist of 5 subjects who will be administered a dose of 10mg propanolol and followed 1-4 weeks.~Data safety and monitoring committee has reviewed the data for safety and instructed the study to continue based on the findings.
- cohort 2 20mg propranolol (Type: ACTIVE_COMPARATOR): This cohort will involve the administration of 5 subjects with 20mg propanolol. The data safety and monitoring committee will review the data for safety when the 5 subjects are recruited and instruct the study to continue depending on the findings.
- cohort 3 40mg propranolol (Type: ACTIVE_COMPARATOR): This cohort will involve the administration of 10 subjects with 40mg propanolol. The data safety and monitoring committee will review the data for safety when the 10 subjects are recruited and instruct the study to continue depending on the findings.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Benefit and Tolerability of a Probiotic Product in Infants With Abdominal Discomfort

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female singleton~* ≥ 2 weeks and ≤ 12 weeks of age~* Exclusively breastfed at screening~* Abdominal discomfort (infant colic) in the week prior to enrollment, according to the statement of the parent(s) and/or guardian(s)~* Episodes of fussy crying that lasted at least 3 hours a day for at least 3 days in the 7 days prior to enrollment, according to the statement of the parent(s) and/or guardian(s)~* Voluntary, written informed consent of the parent(s) and/or guardian(s) to participate in the study~* Born at full term (37-42 after last menstruation period)~* Birth weight: 2500 - 4500 g~* Weight-for-age ≥ 3th and ≤ 97th percentile according to WHO growth tables / charts~* Apparently healthy at birth (Apgar ≥ 8) and at screening visit~* No major complications during pregnancy or at birth~* Mother 19-45 years of age at childbirth~* Ability of parent(s) and/or guardian(s) to attend visits, interviews and willingness to fill out questionnaires~Exclusion Criteria:~* Intolerance to investigational product/its ingredients~* Severe medical condition or illness, congenital abnormality~* Gastrointestinal disorders (e.g. reflux esophagitis)~* Intake of probiotics and/or antibiotics in the week preceding recruitment and during the study~* Formula feeding at screening/randomisation~* Allergy or atopic disease (family history)~* Participation in another study~* Mother's health condition that may interfere with her ability to take care of her infant~* Mother affected by hepatitis B, HIV or Guillain-Barré Syndrome~* Use of antibiotics by the mother in the week

- Gender: ALL
- Minimum Age: 2 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: None

Study Arms:
- Probiotics (Type: ACTIVE_COMPARATOR): None
- Control (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Subdissociative-dose Ketamine Versus Morphine for Prehospital Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* older than 18 years old~* prehospital moderate to severe acute pain, defined as a numeric rating scale score greater than or equal to 5~Exclusion Criteria:~* unstable vital signs (systolic blood pressure \<90 or \>200 mm Hg, pulse rate \<50 or \>150 beats/min, and respiration rate \<10 or \>30 breaths/min)~* pregnancy~* breast-feeding~* altered mental status~* unable to give numeric rating scale scores~* allergy to morphine or ketamine~* acute pulmonary edema~* acute coronary syndrome~* renal or hepatic insufficiency~* patient who received morphine for the same acute pain~* acute psychiatric illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine IV (Type: EXPERIMENTAL): None
- Morphine IV (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* chronic kidney disease stage IV not requiring dialysis;~* expected to initiate dialysis within 18 months;~* 15\<=Glomerular Filtration Rate (GFR)\<=29.~Exclusion Criteria:~* failing renal allograft in place;~* acute or chronic bleeding within 8 weeks prior to screening;~* transfusion of red blood cells within 8 weeks prior to screening;~* poorly controlled hypertension;~* immunosuppressive therapy in the 12 weeks prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- methoxy polyethylene glycol-epoetin beta (Type: EXPERIMENTAL): 120-360 micrograms methoxy polyethylene glycol-epoetin beta subcutaneous (sc) monthly starting dose, for a minimum of 5 months to a maximum of 18 months.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL.
- Epoetin alfa (Type: ACTIVE_COMPARATOR): Patients randomized to the reference arm continued to receive their standard of care dose and regimen of epoetin alfa subcutaneous once per week for a minimum of 5 months to a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL.
- Darbepoetin alfa (Type: ACTIVE_COMPARATOR): Patients randomized to the reference arm continued to receive their standard of care dose and regimen of darbepoetin subcutaneous once every two weeks for a minimum of 5 months and a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of Dermal Matrix in Breast Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All women who are candidates for breast reconstruction using tissue expanders after mastectomy~Exclusion Criteria:~* Other forms of breast reconstruction after mastectomy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DermaMatrix (Type: EXPERIMENTAL): experimental group with DermaMatrix acellular dermis over tissue expanders in addition to skin/soft tissue and muscle to allow for more natural appearing breast and prevention of complications
- Standard of care (Type: ACTIVE_COMPARATOR): standard of care using skin/soft tissue and muscle coverage of tissue expander for breast reconstruction after mastectomy without acellular dermal matrix

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Dietary Conditions on Drug Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-45 years~* Fluent in written and spoken English and is capable of understanding and complying with the protocol~* Medically healthy~* Non-smoker~* Appropriate dietary/over-the-counter/prescription/illicit drug use history~* Body Mass Index between 18.5 and 34.9~* Appropriate use of birth control in females e.g., barrier methods, hormonal contraceptives, Intra Uterine Devices (IUDs)~Exclusion Criteria:~* Known hypersensitivity to administered drugs~* Current neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary or metabolic disease for which administration of the study drugs would be contraindicated~* Current psychiatric or substance use condition that would interfere with study participation~* Diastolic blood pressure \>90 mmHg or a systolic pressure of \>140 mmHg~* Use of medications that would interfere with study participation~* Unwilling or unable to comply with the protocol~* Any other serious disease or condition that might affect life expectancy or make it difficult to successfully manage the subjects according to the protocol~* Females: Pregnancy, breastfeeding, or plans to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Caffeine Maintenance (Type: EXPERIMENTAL): All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo). During the caffeine maintenance condition, participants will ingest 200 mg of caffeine orally in capsules three times daily.
- Placebo Maintenance (Type: PLACEBO_COMPARATOR): All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo). The placebo maintenance condition will be identical to the caffeine maintenance condition, with the exception that the thrice daily capsules will contain placebo (microcrystalline cellulose) rather than containing caffeine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ECOG performance status 0-2~* Life expectancy of greater than 12 months~* No prior history of esophageal surgery or endoscopic treatment of dysplasia~* No prior exposure to sorafenib~* Patients may not be receiving any other investigational agents or any concomitant antineoplastic therapy, with the exception of androgen ablating agents (for patients with prior prostate cancer)~* Age 18 years.~* Patients must have adequate organ and marrow function as defined below:~  * hemoglobin: 8.5 g/dL~ * absolute neutrophil count: 1,500/L~ * platelets: 100,000/L (greater than 35,000/L without transfusion for less than 1 X the institutional upper limit of normal)~ * creatinine less than 1.5 X institutional upper limit of normal~* Ability to understand and the willingness to sign a written informed consent.~Exclusion Criteria:~* A patient will be withdrawn from the study if any of the following events occur while on therapy:~  * Interruption of scheduled therapy for greater than 7 days~ * Intolerable adverse effects which are judged by the investigator to be either physically or psychologically detrimental to the patient~ * Patient decision to discontinue treatment~ * Pregnancy~ * Patient non-compliance with therapy administration~ * Grade 3 or 4 NCI-CTC toxicity attributable to sorafenib~ * Treatment with other chemotherapeutic or investigational anti-neoplastic drugs~ * Disease progression~* HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with sorafenib.Appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- sorafenib (Type: EXPERIMENTAL): sorafenib 2 tablets by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Upgrade the Grains Study: Increasing Whole Grain Consumption in Low-income Children With Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obese (BMI greater than 95th percentile for age and gender)~* Low-income family currently participating in SNAP (food stamps)~* Participant and caregiver speaks either English or Spanish~Exclusion Criteria:~* medications to lower lipid levels (statins), which would affect insulin sensitivity (e.g. metformin, abilify) or which are known to affect serum cholesterol (e.g. carbamazepine).~* Type II diabetes

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- Reimbursement arm (Type: EXPERIMENTAL): Participating caregivers will turn in receipts from grocery store purchases. At each of three study visits, participants in the reimbursement arm will receive reimbursement of up to 10% of their usual SNAP benefits for specific whole grain foods purchased at one of two chain stores in the previous month.
- Control arm (Type: NO_INTERVENTION): Participating caregivers will mail in receipts from grocery store purchases. Participants in the control arm will also be given the same guidance about preferred whole grain foods and whole grain products but will have no specific financial incentive related to purchases of whole grain foods during the 12-week study period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy